Date: June 11, 2019

Time: 1:00 - 2:00 PM EDT

Past Events

Many people in the asthma community view their asthma as an episodic condition rather than a chronic disease, relying on their rescue inhaler to relieve symptoms rather than addressing the underlying inflammation through the use of controller inhalers. The rescue or reliever medication simply provides short-term relief from symptoms as opposed to controller medications which offer long-term benefit and prevention.

Excessive use of relievers (four or more times per week for adults) is indicative of poor asthma control. There are many risks associated with the inappropriate use of rescue medications including decreased quality of life, increased risk of severe, life-threatening asthma attacks and permanent damage to the lungs. If overused, relievers may cause more frequent asthma flare-ups, may lead to frequent hospitalizations and can have an impact on mental and physical activity. New guidelines released by the Global Initiative for Asthma (GINA) address the issues related to over reliance on reliever medications.

On Tuesday, June 11 at 1 PM EDT, Asthma Canada will be hosting a Webinar on Red Flag: Overusing Your Rescue Inhaler.

Our webinars include a Question & Answer session with the guest speaker, giving you the opportunity to ask pressing questions to one of Canada’s leading experts. Don’t miss out!

What you’ll take away:

  • Why must asthma be treated as a chronic disease that needs to be managed; not as episodic?
  • What are the risks of over-reliance?
  • What is good asthma control?
  • What are the new changes to GINA and how does this impact patients?
  • What approaches could lead to better health outcomes?
  • What are some take-home tips and advice?

 

Guest Speaker: Dr. Alan Kaplan (MD, CCFP(EM), FCPC)

Dr. Kaplan is a Family Physician practicing in York Region, Ontario, Canada.

He is the Chairperson of the Family Physician Airways Group of Canada and the past- Chairperson of the Respiratory Section of the College of Family Physicians of Canada. He is a Senate member of the International Primary Care Respiratory Group and a representative of the College of Family Physicians of Canada to the SARS clinical working group. A member of the Health Canada Section on Allergy and Respiratory Therapies, he also co-chairs Health Quality Ontario COPD Community Management standards committee and is a Board member of Thrombosis Canada. Dr. Kaplan is also the Vice President of the Respiratory Effectiveness Group. Dr. Kaplan is also a member of Asthma Canada’s Scientific and Medical Advisory Committee.